Cargando…

P1164: PEGARSPARGASE AND SINTILIMAB FOR NEWLY DIAGNOSED, ADVANCED STAGE NATURAL KILLER T-CELL LYMPHOMA, NASAL TYPE: AN OPEN-LABEL, SINGLE-ARM, PHASE 2 STUDY.

Detalles Bibliográficos
Autores principales:	Xiong, Jie, Cheng, Shu, Wang, LI, Xu, Peng-Peng, Zhao, Wei-LI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431121/ http://dx.doi.org/10.1097/01.HS9.0000971552.07464.0b

Ejemplares similares

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
por: Huang, Huiqiang, et al.
Publicado: (2021)

A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type
por: Xu, Peng-Peng, et al.
Publicado: (2017)

GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
por: Wang, Jing-jing, et al.
Publicado: (2016)

Sintilimab combined with chidamide in the treatment of extranodal nature killer/T-cell lymphoma with secondary hemophagocytic lymphohistiocytosis: Two case reports and literature review
por: Xu, Qing-Yuan, et al.
Publicado: (2022)

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
por: Li, Dailong, et al.
Publicado: (2022)

P1164: IMAGE-BASED DETECTION OF HIGH-GRADE B CELL LYMPHOMAS (DH-L)
por: Avivi, I., et al.
Publicado: (2022)

Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
por: Chen, Xiaofeng, et al.
Publicado: (2023)

Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE/IIE extranodal natural killer/T‐cell lymphoma, nasal type
por: Tian, Shu, et al.
Publicado: (2019)

P1119: CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A PROSPECTIVE MULTICENTER SINGLE-ARM STUDY
por: Zhi-Ming, LI, et al.
Publicado: (2023)

Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
por: Guo, Honghai, et al.
Publicado: (2022)

Five‐year analysis from phase 2 trial of “sandwich” chemoradiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T‐cell lymphoma
por: Zhang, Li, et al.
Publicado: (2015)

Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)
por: Tao, Rong, et al.
Publicado: (2021)

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial
por: Fang, Xuefeng, et al.
Publicado: (2023)

Phase II Study of Gemcitabine, Peg-Asparaginase, Dexamethasone and Methotrexate Regimen for Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Final Analysis With Long-Term Follow-Up and Rational Research for the Combination
por: Wang, Yu, et al.
Publicado: (2022)

Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type
por: Gill, Harinder, et al.
Publicado: (2010)

Treatment outcome of nasal natural killer/T-cell lymphoma
por: Lee, Hyun Jin, et al.
Publicado: (2011)

Delayed Diagnosis of Nasal Natural Killer/T-Cell Lymphoma
por: Villwock, Jennifer A., et al.
Publicado: (2013)

Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial
por: Tian, Zhichao, et al.
Publicado: (2022)

Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab
por: Shi, Yuankai, et al.
Publicado: (2020)

Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study
por: Lu, Nian, et al.
Publicado: (2023)

Newly diagnosed extranodal NK/T-cell lymphoma, nasal type, at the injected left arm after BNT162b2 mRNA COVID-19 vaccination
por: Tachita, Takuto, et al.
Publicado: (2023)

Immunogenicity Measures of Influenza Vaccines: A Study of 1164 Registered Clinical Trials
por: Domnich, Alexander, et al.
Publicado: (2020)

Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report
por: Xu, Jingyan, et al.
Publicado: (2021)

Clinico-Radiologic Findings in Primary Cutaneous Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Mimicking Cellulitis of the Left Arm
por: Kim, Soo Hyun, et al.
Publicado: (2015)

Therapy of newly diagnosed follicular lymphoma
por: Westin, Jason R., et al.
Publicado: (2012)

Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma
por: Wang, Guan-Nan, et al.
Publicado: (2017)

1164. Antibacterial Utilization for Febrile Illnesses and Laboratory-Confirmed Bloodstream Infections in Northern Tanzania
por: Moorthy, Ganga S, et al.
Publicado: (2022)

Metachronous extranodal natural killer/T-cell lymphoma of nasal type and primary testicular lymphoma
por: Maeng, Young-In, et al.
Publicado: (2020)

Primary Orbital Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, without Nasal Involvement
por: Jing, Dalan, et al.
Publicado: (2022)

Rhino-Orbital-Cerebral Mycosis and Extranodal Natural Killer or/and T-Cell Lymphoma, Nasal Type
por: Li, Dong Ming, et al.
Publicado: (2022)

Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial
por: Jiang, Lan-lan, et al.
Publicado: (2021)

Extranodal Natural Killer/T-Cell Lymphoma of the Nasal Type with Skin Metastases
por: Akhrass, Fadi Al, et al.
Publicado: (2016)

Neurolymphomatosis Caused by Nasal-type Extranodal Natural Killer/T-cell Lymphoma
por: Yi, Fang-Fang, et al.
Publicado: (2017)

Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment
por: van Doesum, Jaap A., et al.
Publicado: (2021)

Skin lesion of extranodal natural killer/T‐cell lymphoma nasal type
por: Okumura, Koichiro, et al.
Publicado: (2021)

A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T‐cell lymphoma, nasal type: a multicenter trial in Northwest China
por: Liang, Rong, et al.
Publicado: (2016)

Genetic diversity of newly diagnosed follicular lymphoma
por: Asmann, Y W, et al.
Publicado: (2014)

Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
por: Yan, Zheng, et al.
Publicado: (2020)

Familial Adenomatous Polyposis: Experience from a Study of 1164 Unrelated German Polyposis Patients
por: Friedl, Waltraut, et al.
Publicado: (2005)

SG-APSIC1164: Cost-effectiveness of temporary isolation rooms in acute-care settings in Asia
por: Graves, Nicholas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sq8avn4ijg0ue3eegv8gn8otnd